References

Halki Diabetes Remedy

New Treatment of Diabetes

Get Instant Access

1. National Center for Health Statistics Website. Prevalence of Overweight and Obesity Among Adults: United States, 1999-2002. http:// www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm (accessed on June 2005).

2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2005.

3. Mokdad, A. H.; Ford, E. S.; Bowman, B. A.; Dietz, W H.; Vinicor, F; Bales, V S.; Marks, J. S. JAMA 2003, 289, 76-79.

4. King, H.; Rewers, M. Diabetes Care 1993, 16, 157-177.

5. Ford, E. S.; Williamson, D. F; Liu, S. Am. J. Epidemiol. 1997, 146, 214-222.

6. Klein, B. E. K.; Klein, R.; Lee, K. E. Diabetes Care 2002, 25, 1790-1794.

7. Sattar, N.; Gaw, A.; Scherbakova, O. Circulation 2003, 108, 414-419.

8. Kleinman, J. C.; Donahue, R. P; Harris, M. I. Am. J. Epidemiol. 1999, 128, 389.

9. Harris, M. I.; Klein, R.; Welbom, J. A.; Knuiman, M. W Onset of NIDDM occurs at least 4-7yr before clinical diagnosis. Diabetes Care 1992,15, 815-819.

10. Pan, X. R.; Li, G. W; Hu, Y H.; Wang, J. X.; Yang, W Y; An, Z. X.; Hu, Z. X.; Lin, J.; Xiao, J. Z.; Cao, H. B. et al. Diabetes Care 1997, 20, 537544.

11. Tuomilehto, J.; Lindstrom, J.; Eriksson, J. G.; Valle, T T.; Hamalainen, H.; Ilanne-Parikka, P; Keinanen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M. et al. N. Engl. J. Med. 2001, 344, 1343-1350.

12. The Diabetes Prevention Program (DPP) Research Group. N. Engl. J. Med. 2002, 346, 393-403.

13. Chiasson, J. L.; Josse, R. G.; Gomis, R.; Hanefeld, M.; Karasik, A.; Laakso, M. JAMA 2003, 290, 486-494.

14. Buchanan, T A.; Xiang, A. H.; Peters, R. K.; Kjos, S. L.; Marroquin, A.; Goico, J.; Ochoa, C.; Tan, S.; Berkowitz, K.; Hodis, H. N.; Azen, S. P Diabetes 2002, 51, 2796-2803.

15. 2005 ADA Clinical Practice Guidelines. Diabetes Care 2005, 28, S40.

16. 2005 ADA Clinical Practice Guidelines. Diabetes Care 2005, 28, S41.

17. Alexander, C. M.; Landsman, P B.; Teutsch, S. M.; Haffner, S. M. Diabetes 2003, 52, 1210-1214.

18. Alberti, K. G.; Zimmet, P Z. Diabet. Med. 1998, IS, 539-553.

19. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486.

20. Seaquist, E. In Endocrine Physiology, 1st ed.; Niewoehner, C. B., Ed.; Fence CreekH New Haven, CT, 1998, Chapter 8, p 118.

21. Andersen, D.; Elahi, D.; Brown, J. C. J. Clin. Invest. 1978, 62, 152-161.

22. Dupre, J.; Ross, S. A.; Watcon, D.; Brown, J. C. J. Clin. Endocrinol. Metab. 1973, 37, 826-828.

23. Creutzfeldt, W; Nauck, M. Diabetes Metab. Rev. 1992, 8, 149.

24. Nishi, S.; Seino, Y; Ishida, H. J. Clin. Invest. 1987, 79, 1191-1196.

25. Rhodes, C. J.; Shoelson, S.; Halban, P. A. In Joslin's Diabetes Mellitus, 14th ed.; Baltimore, OH: Lippincott Williams & Wilkins, 2004, Chapter 5, pp 66, 69.

26. Fajans, S. S.; Bell, G.; Polonsky, K. S. N. Engl. J. Med. 2001, 345, 971-980.

27. Ward, W K.; Bolgiano, D. C.; McKnight, B.; Halter, J. B.; Porte, D., Jr. J. Clin. Invest. 1984, 74, 1318-1328.

28. Saltiel, A. R.; Kahn, C. R. Nature 2001, 414, 799-806.

29. Redondo, M. J.; Yu, L.; Hawa, M.; Mackenzie, T; Pyke, D. A.; Eisenbarth, G. S. Diabetologia 2001, 44, 927.

30. Tillil, H.; Kobberline, J. Diabetes 1987, 36, 93-99.

31. Bergenstal, R. M.; Kendal, D. M.; Franz, M. J.; Rubenstein, A. H. In Endocrinology, 4th ed.; DeGroot, L. J., Jameson, J. L., Eds.; WB Saunders: Philadelphia, PA, 2001, Chapter 58, p 822.

32. Medici, F; Hawa, M.; Ianari, A. Diabetologia 1999, 42, 146-150.

34. Pimenta, W; Kortytkowski, M.; Mitrakou, A. JAMA 1995, 273, 1855-1861.

35. Bergman, R. N.; Phillips, L. S.; Cobelli, C. J. Clin. Invest. 1981, 68, 1456-1467.

36. Kahn, S. E. J. Clin. Endocrinol. Metab. 2001, 86, 4047.

37. Shafrir, E. In Ellenberg & Rifkin's Diabetes Mellitus, 6th ed.; Porte, D., Jr., Sherwin, R. S., Baron, A., Eds.; McGraw-Hill: New York, 2003, Chapter 16, p 231.

38. Malaisse, W J. Biochem. Pharmacol. 1982, 31, 3527.

39. Okamoto, H. In Molecular Biology of the Islets of Langerhans; Okamoto, H., Ed.; Cambridge University Press: Cambridge, 1990.

40. Crisa, L.; Mordes, J. P; Rossini, A. A. Diabetes Metab. Rev. 1992, 8, 9.

41. Harada, M.; Makino, S. Ann. Rep. Shionogi Res. Lab. 1992, 42, 70.

42. Araki, E.; Lipes, M. A.; Patti, M. E. Nature 1994, 372, 182.

44. Andrikopoulos, S.; Thorburn, A. W E.; Proietto, J. In Primer on Animal Models of Diabetes; Sima, A. A. F, Shafrir, E., Eds.; Harwood Academic Press: Reading, 2000, p 171.

45. Berdanier, D. D. In Lessons from Animal Diabetes; Shafrir, E., Ed.; Smith-Gordon: London, 1995, p 231.

46. Kawano, K.; Hirashima, T; Mori, S. In Lessons from Animal Diabetes; Shafrir, E., Ed.; Birkhauser: New York, 1996, p 227.

47. Ziv, E.; Shafrir, E. In Lessons from Animal Diabetes; Shafrir, E., Ed.; Smith-Gordon: London, 1995, p 231.

48. University Group Diabetes Program. Diabetes 1970, 19, 747-830.

49. The DCCT Research Group. N. Engl. J. Med. 1993, 329, 977-986.

50. The DCCT Research Group. Diabetes Care 1995, 18, 1415-1427.

51. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA 2002, 287, 2563-2569.

52. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N. Engl. J. Med. 2005, 353, 2643.

53. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA 2003, 290, 2159-2167.

54. UK Prospective Diabetes Study Group. Lancet 1998, 352, 837-853.

55. 2006 ADA Clinical Practice Guidelines. Diabetes Care 2006, 29, S10.

56. UK Prospective Diabetes Study Group. Metabolism 1990, 39, 905-912.

57. Mudaliar, S.; Henry, R. R. In Ellenberg & Rifkin's Diabetes Mellitus, 6th ed.; Porte, D., Jr., Sherwin, R. S., Baron, A., Eds.; McGraw-Hill: New York, 2003, Chapter 32, pp 532-533.

58. Fuhlendorff, J.; Rorsman, P.; Kofod, H.; Brand, C. L.; Rolin, B.; MacKay, P; Shymko, R.; Carr, R. D. Diabetes 1998, 47, 345-351.

59. Moses, R.; Slobodniuk, R.; Boyages, S.; Colagiuri, S.; Kidson, W; Carter, J.; Donnelly, T; Moffitt, P; Hopkins, H. Diabetes Care 1999, 22, 119-124.

60. Horton, E. S.; Clinkingbeard, C.; Gatlin, M.; Foley, J.; Mallows, S.; Shen, S. Diabetes Care 2000, 23, 1660-1665.

61. Rossetti, L.; DeFronzo, R. A.; Gherzi, R. Metabolism 1990, 39, 425-435.

62. Cigolini, M.; Bosello, O.; Zancanaro, C.; Orlandi, P. G.; Fezzi, O.; Smith, U. Diabetes Metab. 1984, 10, 311-315.

63. DeFronzo, R. A.; Barzilai, N.; Simonson, D. C. J. Clin. Endocrinol. Metab. 1991, 73, 1294-1301.

64. DeFronzo, R. A.; Goodman, A. M. N. Engl. J. Med. 1995, 333, 541-549.

65. Bailey, C. J. Biguanides and NIDDM. Diabetes Care 1992, 15, 755-772.

66. Campbell, L. K.; White, J. R. Ann. Pharmacother. 1996, 30, 1255.

67. Yki-Jarvinen, H. N. Engl. J. Med. 2004, 351, 1106-1118.

68. Duez, H.; Chao, Y S.; Hernandez, M.; Torpier, G.; Poulain, P; Mundt, S.; Mallat, Z.; Teissier, E.; Burton, C. A.; Tedgui, A. et al. J. Biol. Chem. 2002, 277, 48051-48057.

69. Diabetes Atherosclerosis Intervention Study Investigators. Lancet 2001, 357, 905-910.

70. Lebovitz, H. E.; Dole, J. F; Patwardhan, R.; Rappaport, E. B.; Freed, M. I. J. Clin. Endocrinol. Metab. 2001, 86, 280-288.

71. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23, 1605-1611.

72. Phillips, L. S.; Grunberger, G.; Miller, E.; Patwardhan, R.; Rappaport, E. B.; Salzman, A. Diabetes Care 2001, 24, 308-315.

73. Sakamoto, J.; Kimura, H.; Moriyama, S. Biochem. Biophys. Res. Commun. 2000, 278, 704-711.

74. Hirsch, I. B. N. Engl. J. Med. 2005, 352, 174-183.

75. Ter Braak, E. Wi; Woodworth, J. R.; Bianchi, R.; Cerimele, B.; Erkelens, D. Wi; Thijssen, J. H. H.; Kurtz, D. Diabetes Care 1996,19, 1437-1440.

76. Nolte, M. A.; Karam, J. H. In Basic and ClinicalPharmacolog, 8th ed; Katzung, B. G., Ed.; Appleton and Lang: Stamford, CT, 2001, p 711.

77. Rabkin, R.; Ryan, M. P.; Duckworth, W C. Diabetologia 1984, 27, 351-357.

78. Barlocco, D. Curr. Opin. Invest. Drugs 2003, 4, 1240-1244.

79. Wright, A.; Burden, A. C.; Paisey, R. B.; Cull, C. A.; Holman, R. R. Diabetes Care 2002, 25, 330-336.

80. Pugh, J. A.; Wagner, M. L.; Sawyer, J.; Ramirez, G.; Tuley, M.; Friedberg, S. J. Diabetes Care 1992, 15, 953-959.

81. UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352, 837-853.

82. Whitehouse, F; Kruger, D. F; Fineman, M.; Shen, L.; Ruggles, J. A.; Maggs, D. G.; Weyer, C.; Kolterman, O. G. Diabetes Care 2002, 25, 724-730.

83. Hollander, P. A.; Levy, P; Fineman, M.; Shen, L.; Maggs, D. G.; Strobel, S. A.; Weyer, C.; Kolterman, O. G. Diabetes Care 2003, 26, 784-790.

84. DeFronzo, R. A.; Ratner, R. E.; Han, J.; Kim, D. D.; Fineman, M. S.; Baron, A. D. Diabetes Care 2005, 28, 1092-1100.

85. Exenatide-113 Clinical Study Group. Diabetes Care 2004, 27, 2628-2635.

86. Kendall, D. M.; Riddle, M. C.; Rosenstock, J.; Zhuang, D.; Kim, D. D.; Fineman, M. S.; Baron, A. D. Diabetes Care 2005, 28, 1083-1091.

87. Pederson, R. A.; White, H. A.; Schlenzig, D.; Pauly, R. P; McIntosh, C. H.; Demuth, H. U. Diabetes 1998, 47, 1253-1258.

88. Ahren, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Diabetes Care 2004, 27, 2874-2880.

89. Trumper, A.; Trumper, K.; Horsch, D. J. Endocrinol. 2002, 174, 233-246.

90. Nauck, M. A.; Heimesaat, M. M.; Orskov, C.; Holst, J. J.; Ebert, R.; Creutzfeldt, Wi J. Clin. Invest. 1993, 91, 301-307.

91. Frame, S.; Cohen, P. Biochem. J. 2001, 359, 1-16.

92. Zhang, Z. Y; Lee, S. Y Expert Opin. Invest. Drugs 2003, 12, 223.

93. Skyler, J. S.; Cefalu, W T; Kourides, I. A.; Landschulz, W H.; Balagtas, C. C.; Cheng, S. L.; Gelfand, R. A. Lancet 2001, 357, 331-335.

94. Cefalu, W T; Skyler, J. S.; Kourides, I. A.; Landschulz, W H.; Balagtas, C. C.; Cheng, S.; Gelfand, R. A. Ann. Intern. Med. 2001,134, 203-207.

95. Gruessner, A. C.; Sutherland, D. E.; Dunn, D. L. J Am. Soc. Nephrol. 2001, 12, 2490-2499.

96. Shapiro, A. M.; Lakey, J. R.; Ryan, E. A.; Kobutt, G. S.; Toth, E.; Warnock, G. L.; Kneteman, N. M.; Rajotte, R. V N. Engl. J. Med. 2000, 343, 230-238.

97. Ryan, E. A.; Lakey, J. R. T; Paty, B. W; Imes, S.; Korbutt, G. S.; Kneteman, N. M.; Bigam, D.; Rajotte, R. V; Shapiro, A. M. J. Diabetes 2002, 51, 2148-2157.

98. Hori, Y; Rulifson, I. C.; Tsai, B. C. Proc. Natl. Acad. Sci. 2002, 99, 16105-16110.

99. Lumelsky, N.; Blondel, O.; Laeng, P Science 2001, 292, 1389-1394.

100. Hayashi, K. Y; Tamaki, H.; Handa, K. Arch. Histol. Cytol. 2003, 66, 163-174.

101. Bonner-Weir, S. J. Mol. Endocrinol. 2000, 24, 297-302.

Biographies

Lowell Schmeltz received his undergraduate degree from the University of Michigan and medical degree from the University of Pittsburgh School of Medicine. He completed his internship and residency in Internal Medicine at the Feinberg School of Medicine of Northwestern University in Chicago, IL. Dr Schmeltz is currently an endocrinology fellow at Northwestern University, pursuing clinical research in diabetes management, and has published online updates of various endocrinology topics in collaboration with Dr J Larry Jameson for Harrison's Principles of Internal Medicine.

Boyd Metzger was an undergraduate at the University of South Dakota and received his MD from the University of Iowa. He was an Intern, Medical Resident, and Resident in Endocrinology & Metabolism at Michael Reese Hospital in Chicago, and a Research Fellow in the Department of Biological Chemistry at Washington University in St Louis. In 1967, he joined the faculty of Northwestern University School of Medicine in the Department of Medicine and the Center for Endocrinology Metabolism and Nutrition. Currently, he is Tom D Spies Professor of Metabolism & Nutrition. His research interests have included the pathophysiology and prevention of type 2 diabetes mellitus, regulation of intermediary metabolism in normal and diabetic pregnancy, and the intrauterine, perinatal, and life-long impact of the metabolic environment of maternal diabetes. Because gestational diabetes is a common precursor of type 2 diabetes, he has used it as a model for studies of insulin resistance and b-cell function in subjects at high risk for progression to overt diabetes. Currently, his is Principal Investigator of the Hyperglycemia & Adverse Pregnancy Outcome (HAPO) Study, an international, multicenter epidemiological study aimed at determining the level of maternal hyperglycemia associated with clinically meaningful risk of adverse pregnancy outcome. The data should permit investigators and clinicians to establish 'outcome-based' criteria for the diagnosis of gestational diabetes.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 417-458

Was this article helpful?

0 0
Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment